医学
AJCC分段系统
肝内胆管癌
淋巴结
T级
TNM分期系统
登台系统
癌症分期
癌症
总体生存率
癌症登记处
内科学
普通外科
阶段(地层学)
肿瘤科
肝细胞癌
古生物学
生物
作者
Xu Feng Zhang,Feng Xue,Jin He,Sorin Alexandrescu,Hugo P. Marques,Luca Aldrighetti,Shishir K. Maithel,Carlo Pulitano,Todd W. Bauer,Feng Shen,George A. Poultsides,O. Soubrane,Guillaume Martel,B. Groot Koerkamp,Itaru Endo,Yi Lv,Timothy M. Pawlik
出处
期刊:Hpb
[Elsevier]
日期:2021-09-01
卷期号:23 (9): 1456-1466
被引量:7
标识
DOI:10.1016/j.hpb.2021.02.009
摘要
To improve the prognostic accuracy of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for intrahepatic cholangiocarcinoma (ICC) with establishment and validation of a modified TNM (mTNM) staging system.Data on patients who underwent curative-intent resection for ICC was collected from 15 high-volume centers worldwide (n = 643). An external validation dataset was obtained from the SEER registry (n = 797). The mTNM staging system was proposed by redefining T categories, and incorporating the recently proposed N status as N0 (no lymph node metastasis [LNM]), N1 (1-2 LNM) and N2 (≥3 LNM).The 8th AJCC TNM staging system failed to stratify overall survival (OS) of stage II versus IIIA, stage IIIB versus IV, as well as overall stage III versus IV among all patients from the two databases, as well as stage I versus II, and stage III versus III among patients who had ≥6 LNs examined. There was a monotonic decrement in survival based on the proposed mTNM staging classification among patients derived from both the multi-institutional (Median OS, stage I 69.8 vs. II 37.1 vs. III 18.9 vs. IV 16.4 months, all p < 0.05), and SEER (Median OS, stage I 87.0 vs. II 29.3 vs. III 17.7 vs. IV 14.2 months, all p < 0.05) datasets, which was also verified among patients who had ≥6 lymph node harvested from both databases.The modified TNM staging system for ICC using the new T and N definitions provided an improved means to stratify patients relative to long-term OS versus the 8th AJCC staging.
科研通智能强力驱动
Strongly Powered by AbleSci AI